Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Ensuring rational introduction and responsible use of new TB tools: outcome of an ERS multisector consultation.

Migliori GB, Lienhardt C, Weyer K, van der Werf MJ, Blasi F, Raviglione MC.

Eur Respir J. 2014 Dec;44(6):1412-7. doi: 10.1183/09031936.00132114. No abstract available.

2.

Stop TB Partnership has provided treatments for 10 million people in 6 years.

[No authors listed]

Wkly Epidemiol Rec. 2007 Jun 1;82(22/23):206-7. English, French. No abstract available.

3.

The worldwide epidemic of multidrug-resistant tuberculosis.

The Lancet Infectious Diseases.

Lancet Infect Dis. 2011 May;11(5):333. doi: 10.1016/S1473-3099(11)70105-0. No abstract available.

PMID:
21530885
4.

Tuberculosis.

Garner P, Holmes A.

Clin Evid. 2002 Jun;(7):747-56. Review. No abstract available. Update in: Clin Evid. 2002 Dec;(8):819-28.

PMID:
12230701
5.

The threat of multidrug resistance: is tuberculosis ever untreatable or uncontrollable?

Gleissberg V.

Lancet. 1999 Mar 20;353(9157):998-9. No abstract available.

PMID:
10459924
6.

Editorial: the treatment of multi-drug resistant tuberculosis--a return to the pre-antibiotic era?

Ollé-Goig JE.

Trop Med Int Health. 2006 Nov;11(11):1625-8. No abstract available.

7.

Tuberculosis.

Garner P, Holmes A, Ziganshina L.

Clin Evid. 2004 Jun;(11):1081-93. Review. No abstract available. Update in: Clin Evid. 2005 Dec;(14):1026-37.

PMID:
15652053
8.

Control of tuberculosis in India.

Mohapatra PR.

Lancet. 2003 Oct 11;362(9391):1243. No abstract available.

PMID:
14568763
9.

Essential components of a tuberculosis control program within Australia.

National Tuberculosis Advisory Committee.

Commun Dis Intell Q Rep. 2014 Dec 31;38(4):E397-400. No abstract available.

10.

Tuberculosis.

Garner P, Holmes A, Ziganshina L.

Clin Evid. 2005 Dec;(14):1026-37. Review. No abstract available.

PMID:
16620446
11.

Tuberculosis.

Garner P, Holmes A.

Clin Evid. 2002 Dec;(8):819-28. Review. No abstract available. Update in: Clin Evid. 2004 Jun;(11):1081-93.

PMID:
12603914
12.

Beyond directly observed therapy for tuberculosis.

Nolan CM.

Chest. 1997 May;111(5):1151-3. No abstract available.

PMID:
9149558
13.

Acquired multidrug-resistant tuberculosis in an immunocompetent adolescent.

Karande S, Kelkar A, Jagiasi A, Kulkarni M.

Pediatr Infect Dis J. 2002 Jun;21(6):577-8. No abstract available.

PMID:
12182392
14.

Drug resistant tuberculosis: back to sanatoria, surgery and cod-liver oil?

Veen J.

Eur Respir J. 1995 Jul;8(7):1073-5. No abstract available.

15.

'Multidrug'-resistant tuberculosis. It is time to focus on the private sector of medicine.

Sbarbaro JA.

Chest. 1997 May;111(5):1149-51. No abstract available.

PMID:
9149557
16.

Tuberculosis control goals unlikely to be met by 2005.

Sharma DC.

Lancet. 2004 Apr 3;363(9415):1122. No abstract available.

PMID:
15068013
17.

World Health Organization fact sheet. Tuberculosis.

World Health Organization.

Saudi Med J. 2004 Aug;25(8):1136-8. No abstract available.

PMID:
15457607
18.

[Study on the efficacy and safety of short-term treatment including fluoroquinolones anti-tuberculosis drugs for rifampicin resistant pulmonary tuberculosis].

Kang WL, Xie YG, Tan WG, Chu NH, Li L, You YH, Yang YZ, Wang XM, Yan XL, Miao ZP, Duanmu HJ.

Zhonghua Liu Xing Bing Xue Za Zhi. 2009 Feb;30(2):179-83. Chinese.

PMID:
19565883
19.

Multidrug-resistant tuberculosis (MDR-TB): epidemiology, prevention and treatment.

Ormerod LP.

Br Med Bull. 2005 Jun 14;73-74:17-24. Print 2005. Review.

PMID:
15956357
20.

Management of contacts of multidrug-resistant tuberculosis patients in the European Union and European Economic Area.

van der Werf MJ, Sandgren A, Manissero D.

Int J Tuberc Lung Dis. 2012;16(3):426. doi: 10.5588/ijtld.11.0605. No abstract available.

PMID:
22640458

Supplemental Content

Support Center